Study on Using Genomically Guided Radiation Therapy for Treating Triple Negative Breast Cancer

Inclusion Criteria

• Must have had breast conservation therapy, including a lumpectomy and evaluation of lymph nodes in the armpit area.
• Must have a confirmed diagnosis of Triple Negative breast cancer through a tissue biopsy.
• Must have enough tissue available to calculate a specific genomic score (RSI).
• The cancer must not show overexpression of HER2, as determined by specific medical tests.
• The cancer must show less than 10% expression of hormone receptors (estrogen and progesterone) based on medical guidelines.
• Must have a life expectancy of more than 16 weeks.
• Must have a Karnofsky Performance Status (KPS) score of 70 or higher, indicating the ability to care for oneself.
• Must be 18 years or older.
• If surgery was performed within the last 14 days, the participant must have recovered and been cleared by their surgeon.
• There is no restriction on previous treatments received.
• Women who can become pregnant and sexually active men must agree to use effective birth control during the study.
• Must be able to sign an informed consent form, or have a family member or healthcare proxy sign on their behalf before joining the study.

Exclusion Criteria

• Have had major surgery or a significant injury that has not healed within 14 days before starting the study.
• Are pregnant or breastfeeding.
• Have positive surgical margins, meaning cancer cells are found at the edge of the tissue removed during surgery.
• Have a history of allergy or sensitivity to any of the study drugs or their components.
• Have metastatic breast cancer, meaning the cancer has spread to other parts of the body.